Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Bronchiolitis Obliterans Syndrome
Interventions
DRUG

Itacitinib

Itacitinib administered orally at the specified dose.

Trial Locations (9)

15213

UPMC, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

19140

Temple University Department of Thoracic Medicine and Surgery, Philadelphia

27710

Duke University Health System, Durham

44195

Cleveland Clinic, Cleveland

90095

University of California, Los Angeles - David Geffen School of Medicine, Los Angeles

02115

Brigham and Women'S Faulkner Hospitals Inc, Boston

03000

Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven

M5G 2N2

University Health Network Toronto General Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY